Case Report – The Role of New Combination of ADC (Enfortumab vedotin and Immunotherapy (Keytruda)

Case Report – The Role of New Combination of ADC (Enfortumab vedotin and Immunotherapy (Keytruda) in recurrent and refractory advanced Urothelial Cancer – giving patients doomed to death a New Lease of Life. Mr. ASLAN MUKASHEV, a 45 years old male patient complaints of hematuria and lower back pain for 2 months.   History of swelling in right flank for 1 month. Status post UB resection in 2012.   Status post 4 cycles of Chemotherapy (Gemcitabine + Cisplatin in 2012).   Patient was not on any treatment during the period of 2012 to 2021   In 2021 history of alternative medicine and history of procedure in the lower back area for ? draining of fluid recovered after 1 day.

Read More »

Ready to Discuss a Case?

Book an in-person or online consultation today.

Get Expert Guidance Instantly

Share your medical reports directly with us on WhatsApp and receive a quick second opinion from Dr. Manish Singhal.


Our team will review your case and guide you on the best next steps—fast, simple, and secure.